Assessment of Organ Failure Risk Predictions in ICU
Launched by ETH ZURICH · Feb 3, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how well doctors in the Intensive Care Unit (ICU) can predict the risk of organ failure in patients who are critically ill. Specifically, it will compare the doctors’ predictions to advanced computer models that have been developed for this purpose. The goal is to see if experienced ICU doctors can make predictions about potential organ failure as accurately as these computer models.
To participate in this study, you need to be at least 18 years old and have been admitted to the ICU in an emergency situation, with an arterial line (a tube inserted into a blood vessel to monitor blood pressure and take blood samples) already in place. Unfortunately, patients who have certain neurological conditions affecting their awareness, those on specific heart support machines, or those receiving end-of-life care are not eligible. If you join the study, you won't have to change your treatment; the doctors will just track how well they can predict organ failure based on your condition and treatment in the ICU.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patient minimum age of 18 years
- • emergency admission to the ICU
- • arterial line in place
- Exclusion Criteria:
- • documented refusal (on the general consent form) to participate to clinical research
- • patients with neurologic conditions that impair the patient's level of consciousness (including, but not limited to stroke, traumatic brain injury, intracranial hemorrhage, CNS infections; except polytrauma)
- • patients on mechanical circulatory support systems (IABP, VA-ECMO, Impella, VAD) or extracorporeal membrane oxygenation (VV-ECMO) at any time during their ICU stay;
- • patients receiving end-of-life care or are admitted for the sole purpose of evaluating organ donation
About Eth Zurich
ETH Zurich, a prestigious institution known for its cutting-edge research and innovation, is a leading sponsor of clinical trials focused on advancing medical science and improving patient outcomes. With a strong emphasis on interdisciplinary collaboration, ETH Zurich leverages its expertise in engineering, technology, and life sciences to explore novel therapeutic approaches and enhance healthcare delivery. The institution is committed to adhering to rigorous ethical standards and regulatory compliance, ensuring the integrity and scientific validity of its clinical research initiatives. Through its sponsorship, ETH Zurich aims to contribute significantly to the development of transformative treatments and interventions that address critical healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Martin Faltys, Dr. med.
Principal Investigator
Insel Gruppe AG, University Hospital Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported